Gamalec Gamalec (1) ; Gamalec Gamalec (2) / Fadila Khetmi, chant [acc. voc. et instr.]

[Traditions. Afrique du Nord. Tunisie]

Ouenabi Abliti (1) ; Ouenabi Abliti (2) / Dalila Taliana, chant [acc. voc. et instr.]

[Traditions. Afrique du Nord. Tunisie]

Nari Deloûna (1) ; Nari Deloûna (2) / Dalila Taliana, chant [acc. voc. et instr.]

[Traditions. Afrique du Nord. Tunisie]

Ouaad Kelemni (1) ; Ouaad Kelemni (2) / Dalila Taliana, chant [acc. voc. et instr.]

[Traditions. Afrique du Nord. Tunisie]

Ya Raiss (1) ; Ya Raiss (2) / Dalila Taliana, chant [acc. voc. et instr.]

[Traditions. Afrique du Nord. Tunisie]

How High Dose(s) of Oral Vitamin D3 Can Correct Insufficiency in a Non Supplemented Rheumatologic Population ?

Introduction: 700 to 1000 UI Vitamin D/day prevent 20% of fall and fracture. Higher dosage could prevent other health problems, such as immune diseases. Adherence to oral daily vitamin D supplementation is low. There is no guideline on how to supplement patients with rheumatic diseases. We evaluated if 1-2 dose(s) of 300'000 UI oral vitamin D3 was enough to reach an optimal level of 25-OH vitamin D in late winter in patients with insufficiency. Methods: During November 2009 (M0) patients attending our Rheumatology Outpatient Clinic had a blood test to measure 25-OH vitamin D. Results were classified as: deficiency <10µg/l, insufficiency 10µg/l to 30µg/l and normal >30µg/l. Patients on daily oral vitamin D3 or who received a single high dose of vitamin D3 in the last 6 months and patients with deficiency or normal results were excluded. Patients included received a single dose of 300'000 IU of oral vitamin D3 and were asked to come back for a blood test for 25-OH vitamin D after 3 (M3) and 6 months (M6). If they were still insufficient at M3, they received a second high dose of 300'000 IU of oral vitamin D3. Results: 292 patients had their level of 25-OH vitamin D determined at M0. 141 patients (70% women) had vitamin D insufficiency (18.5µg/l (10.2-29.1)) and received a prescription for a single dose of 300'000 IU of oral vitamin D3. Men and women were not statistically different in term of age and 25-OH vitamin D level at M0. 124/141 (88%) patients had a blood test at M3. 2/124 (2%) had deficiency (8.1µg/l (7.5-8.7)), 50/124 (40%) normal results (36.7µg/l (30.5-56.5)). 58% (72/124) were insufficient (23.6µg/l (13.8-29.8)) and received a second prescription for 300'000 IU of oral vitamin D3. Of the 50/124 patients who had normal results at M3 and did not receive a second prescription, 36 (72%) had a test at M6. 47% (17/36) had normal results (34.8µg/l (30.3-42.8)), 53% (19/36) were insufficient (25.6µg/l (15.2-29.9)). Out of the 54/72 (75%) patients who received a second prescription, 28/54 (52%) had insufficiency (23.2µg/l (12.8-28.7)) and 26/54 (48%) had normal results (33.8µg/l (30.0-43.7)) at M 6. Discussion: This real life study has shown that one or two oral bolus of 300'000 IU of vitamin D3 in autumn and winter was not enough to completely correct hypovitaminosis D but was a good way of preventing a nadir of 25-OH vitamin D usually observed in spring in a Swiss rheumatologic population.

D-3 Dependent Adult Abuse Report, July 1, 2013-December 31, 2013

D-3 Dependent Adult Abuse Report

D-3 Dependent Adult Abuse Report, January 1, 2014 - June 31, 2014

D-3 Dependent Adult Abuse Report

Alterações anatômicas e físico-químicas associadas ao armazenamento refrigerado de pêssegos 'Aurora-1' e 'Dourado-2 '

O presente trabalho objetivou avaliar as características anatômicas e físico-químicas de pêssegos (Prunus persica (L.) Batsch) 'Aurora-1' e 'Dourado-2', armazenados em diferentes temperaturas e períodos. No primeiro experimento, os frutos foram armazenados a 0, 3 e 6ºC por 14, 21, 28 e 35 dias (mais dois dias de simulação à comercialização, sob 25ºC). No segundo experimento, os frutos foram armazenados a 0 e 3ºC por 7, 14, 21, 28 e 35 dias (mais dois dias de simulação à comercialização, sob 25ºC). O delineamento experimental empregado foi inteiramente ao acaso, em esquema fatorial, com quatro repetições em parcelas de seis frutos. Pêssegos 'Dourado-2', após sete dias de armazenamento a 3ºC ou 14 dias de armazenamento a 0ºC, apresentaram lanosidade caracterizada pela queda brusca na firmeza e pouca sucosidade. Os sintomas no mesocarpo foram caracterizados pelo afastamento das paredes de células adjacentes e acúmulo de substâncias pécticas no interior das células e dos espaços intercelulares. Pêssegos 'Aurora-1' sofreram redução na firmeza sem comprometer a qualidade dos frutos, podendo ser conservados por até 35 dias a 0 e 3ºC; mesmo aos 35 dias de armazenamento, o mesocarpo não apresentou alterações típicas da lanosidade. Aos 35 dias de armazenamento a 6ºC, os frutos de ambas cultivares estavam sobremaduros.

Lapatax: Safety profile of neoadjuvant lapatinib combined with docetaxel in Her 2/neu overexpressing breast cancer - EORTC protocol 10054

Objective: To assess the safety/tolerability of the combination lapatinib (L) and docetaxel (D) in patients with Her 2/neu overexpressing breast cancer (BC). This study is important as it will define how to deliver lapatinib with taxotere, a highly active drug in breast cancer. Patients and Methods: Female patients (pts) with locally advanced, inflammatory or large operable BC were treated with escalating doses of L from 1000 to 1250 mg/day, in combination with D given IV every 21 days at doses ranging from 75 to 100 mg/m2 for 4 cycles. At least 3 pts were treated at each dose level. The definition of dose limiting toxicity (DLT) is based on the toxicity assessed at cycle 1 as follows: any grade 3−4 non hematological toxicity, ANC < 0.5 G/L lasting for 7 days or more, febrile neutropenia or thrombocytopenia <25 G/L. GCSF was not permitted as primary prophylaxis. Core biopsies were mandatory at baseline and after cycle 4. Pharmcokinetic (PK) samples were collected on day 1 of cycles 1 and 2. Results: To date, 18 pts with a median age of 53 years (range 36−65) have been enrolled at 5 Dose Levels (DLs). The toxicity profile for 18 patients (68 documented cycles) is summarized below. At DL5 (1000/100), 2 pts had DLTs (neutropenia grade 4 _7 days and febrile neutropenia), and 3 additional pts were enrolled with primary prophylactic G-CSF. As expected, the safety profile improved and the dose escalation will continue with prophylactic G-CSF to investigate DL6 (1250/100). These findings are consistent with published Phase I data for this combination [1]. N= 18 patients n (%) Grade 1 Grade 2 Grade 3 Grade 4 neutropenia 1 (6) 3 (17) 13 (72) febrile neutropenia 2 (11) fatigue 8 (44) 7 (39) diarrhoea 9 (50) 3 (17) pain: joint/muscle/other 5 (28)/4 (22)/3 (17) 4 (22)/4 (22)/3 (17) 0/0/1 (6) constipation 2 (11) 3 (17) 1 (6) elevated transaminases SGPT/SGOT 7 (39)/5 (28) Conclusions: The main toxicity of the L + D combination is haematological and was reached at DL5 (1000/100), without primary GCSF. An additional DL6 with primary prophylactic GCSF is being investigated (1250/100). PK data will be presented at the meeting plus the recommended dose for phase II studies.

1.° Donati grammatica. — 2.° Bedae, Presbyteri, liber de schematibus et tropis. — 3.° Ejusdem liber de arte metrica. — 4.° Anonymi libellus de astrologia. — 5.° Anonymi tractatus de computo. — Hujusce codicis pars decimo, pars undecimo, nonnulla decimo tertio saeculo videntur exarata.

Colbertinus

1.° Glossarium vetus. — 2.° Ciceronis synonyma. — 3.° Senecae, Publii Syri et aliorum sententiae. — 4.° Eucherii, Episcopi, glossae spiritales : maxima pars desideratur. — 5.° Glossae in Horatii libros carminum, epodon, de arte poëtica et epistolarum : nonnulla passim desiderantur. — Hujusce codicis pars decimo ; pars duodecimo saeculo videtur exarata.

Puteanus

1.° Anonymi tractatus de computo ecclesiastico : praemittuntur 1.° scholium quo definitur numerus calendarum, nonarum et iduum cujuslibet mensis ; 2.° calendarium ; 3.° rythmus de terminis Quadragesimalibus et Paschalibus, et de termino Rogationum. — 2.° Aurelii Ambrosii Macrobii commentariorum in somnium Scipionis libri duo : sub finem nonnulla desiderantur.

Colbertinus